TradingKey – Amgen (AMGN) has multiple pipeline programs in October that should advance the programs, while newer products help replace the biosimilar and price competition erosion on older products. Amgen closed trading on October 7 at $413.08, up $10.48 or 2.60% on the day and down 7.6% from the August 25, 52 week high of $447.03.

What is interesting is how much more diversified the growth story has become. Repatha has continued to post strong cardiovascular growth, while the latest data for Imdelltra has expanded its role in small cell lung cancer, and Tezspire has posted positive Phase 3 data in eosinophilic esophagitis (EoE), and dazodalibep has also produced strong Phase 3 data in autoimmune disorders. MariTide is still the larger…